• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体外自凝全血中的凝血酶原片段1+2、凝血酶-抗凝血酶III复合物及纤维蛋白肽A。添加肝素及抗凝血酶III缺乏的影响。

Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.

作者信息

Herren T, Straub P W, Haeberli A

机构信息

Department of Medicine, University of Bern, Switzerland.

出版信息

Thromb Haemost. 1994 Jan;71(1):49-53.

PMID:8165646
Abstract

Previous in vitro studies using spontaneously clotting whole blood revealed thrombin formation and high fibrinopeptide A (FPA) concentrations measured during incubation time. This occurred in spite of normal concentrations of thrombin antagonists present in the blood of the healthy subjects examined. However, there are several reports showing that in vivo increased thrombin-antithrombin III-complex (TAT) concentrations and relatively low FPA concentrations may occur e.g. in patients with (pre)thrombotic disorders. These in vivo findings indicate more effective thrombin inhibition by antithrombin III, with almost no fibrin formation. To find an explanation for the differences observed in vitro and in vivo, we extended the in vitro studies by measuring concentrations of prothrombin fragment 1 + 2 (F1 + 2), TAT and FPA at several time points until 30 min. Our goal was to test whether thrombin at least initially is neutralized by antithrombin III, resulting in a lack of fibrin formation, either in the absence or in the presence of heparin (0.2 and 0.5 U/ml whole blood, respectively). In the absence of heparin a simultaneous increase in the concentrations of F1 + 2, TAT and FPA was observed. Thrombin was only partially neutralized by antithrombin III and large amounts of fibrin were formed. The addition of heparin virtually suppressed thrombin formation since the F1 + 2 concentration remained low. Moreover, the small amounts of thrombin formed were neutralized by antithrombin III to a greater extent than in the absence of heparin.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

以往使用自发凝血全血进行的体外研究显示,在孵育期间可检测到凝血酶形成以及高浓度的纤维蛋白肽A(FPA)。尽管在所检测的健康受试者血液中存在正常浓度的凝血酶拮抗剂,但仍出现了这种情况。然而,有几份报告表明,例如在患有(前)血栓形成性疾病的患者体内,可能会出现凝血酶 - 抗凝血酶III复合物(TAT)浓度升高以及相对较低的FPA浓度。这些体内研究结果表明抗凝血酶III对凝血酶的抑制作用更有效,几乎没有纤维蛋白形成。为了找出体外和体内观察到的差异的原因,我们通过在几个时间点直至30分钟测量凝血酶原片段1 + 2(F1 + 2)、TAT和FPA的浓度来扩展体外研究。我们的目标是测试在不存在或存在肝素(分别为0.2和0.5 U/ml全血)的情况下,凝血酶至少在最初是否被抗凝血酶III中和,从而导致纤维蛋白形成缺失。在不存在肝素的情况下,观察到F1 + 2、TAT和FPA浓度同时升高。凝血酶仅被抗凝血酶III部分中和,并且形成了大量纤维蛋白。加入肝素实际上抑制了凝血酶形成,因为F1 + 2浓度保持较低。此外,与不存在肝素时相比,形成的少量凝血酶被抗凝血酶III更大程度地中和。(摘要截断于250字)

相似文献

1
Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.体外自凝全血中的凝血酶原片段1+2、凝血酶-抗凝血酶III复合物及纤维蛋白肽A。添加肝素及抗凝血酶III缺乏的影响。
Thromb Haemost. 1994 Jan;71(1):49-53.
2
Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.低分子量肝素(速碧林)与普通肝素对体内血栓形成部位凝血激活的影响。
Thromb Haemost. 1994 Dec;72(6):831-5.
3
Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.关于鱼精蛋白对人凝血系统激活部位的普通肝素和低分子量肝素(速避凝)的中和作用的研究。
Thromb Haemost. 1995 Mar;73(3):439-43.
4
Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2.通过针对活化片段的检测方法,包括一种用于凝血酶原片段F1 + 2的新型酶联免疫吸附测定法,来测量心脏直视手术期间的凝血酶生成、失活和表达。
Thromb Haemost. 1993 Aug 2;70(2):253-8.
5
Measurement of markers of activated coagulation in antithrombin III deficient subjects.抗凝血酶III缺乏症患者中活化凝血标志物的测定。
Thromb Haemost. 1992 May 4;67(5):542-4.
6
[Prothrombin fragment 1+2 (F1+2), thrombin-antithrombin III complex(TAT) and thrombophilia parameters in orally anticoagulated patients with inferior vena cava filters].口服抗凝治疗的下腔静脉滤器置入患者的凝血酶原片段1+2(F1+2)、凝血酶-抗凝血酶III复合物(TAT)及血栓形成倾向参数
Wien Med Wochenschr. 1993;143(5):95-8.
7
In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole blood.关于枸橼酸化、重组水蛭素化和肝素化全血中凝血酶生成的体外研究。
Thromb Res. 1991 Dec 1;64(5):589-96.
8
Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?心脏手术中的凝血酶生成:肝素是理想的抗凝剂吗?
Thromb Haemost. 1993 Aug 2;70(2):259-62.
9
[Changes in antithrombin III, prothrombin fragment 1 + 2 and thrombin-antithrombin III complex following implantation of a coronary Palmaz-Schatz stent].[冠状动脉Palmaz-Schatz支架植入后抗凝血酶III、凝血酶原片段1+2及凝血酶-抗凝血酶III复合物的变化]
Z Kardiol. 1995 Jan;84(1):22-9.
10
[Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].[颅内出血与止血。通过测定和随访凝血激活产物对颅内出血患者进行监测]
Infusionsther Transfusionsmed. 1994 Aug;21(4):244-50.